Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results
Received FDA approval for Eversense® 365 Continuous Glucose Monitoring system and launched Eversense 365 with commercial partner, AscensiaPatient ...
Nasdaq10d
Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results
Its subsidiaries (referred to collectively as PHC Group) include PHC Corporation, Ascensia Diabetes Care Holdings AG, Epredia Holdings ... Ascensia Diabetes Care logo and Contour are ...
Morningstar15d
Eversense 365 and SweetSpot Integrate Software to Optimize Diabetes Care
A media kit for Eversense 365, including images, logos and further information ... Ascensia Diabetes Care Holdings AG, Epredia Holdings Ltd., LSI Medience Corporation, Mediford Corporation ...
Nasdaq10d
Senseonics Reports FDA Approval and Launch of Eversense® 365, Achieving 56% Patient Growth in 2024
Its subsidiaries (referred to collectively as PHC Group) include PHC Corporation, Ascensia Diabetes Care Holdings AG, Epredia Holdings ... Ascensia Diabetes Care logo and Contour are ...
Taiwan News15d
Eversense 365 and SweetSpot Integrate Software to Optimize Diabetes Care
Senseonics and Ascensia integrate software between SweetSpot and Eversense 365, the world’s first and only One Year CGM system. SweetSpot partners with endocrinology practices t ...
Yahoo Finance9d
FDA clears Epredia’s digital pathology solution
UK-based biotech company Epredia has received 510(k) clearance from the US Food and Drug Administration (FDA) for the E1000 Dx, a digital pathology workflow solution for streamlining laboratory ...
Business Wire10d
Epredia Receives U.S. FDA 510(K) Clearance for the E1000 Dx™ Digital Pathology Solution Designed to Improve Laboratory Workflow in Cancer Diagnostics
PORTSMOUTH, N.H. & KALAMAZOO, Mich.--(BUSINESS WIRE)--Epredia, a global leader in precision cancer diagnostics and subsidiary of PHC Holdings Corporation (TSE: 6523), today announced U.S. Food and ...